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A B S T R A C T

Background: The purpose of this study is to assess how the COVID-19 pandemic affected cancer screening at a large tertiary care setting in the city of Karachi, the third
largest city in the world, and to identify if there has been any decrease in cancer screening during the ongoing pandemic.
Methods: A retrospective observational study was conducted at the clinical chemistry laboratory at the Department of Pathology & Laboratory Medicine, Aga Khan
University Hospital (AKUH), Karachi Pakistan. Data for test volumes was extracted from the Integrated Laboratory Management System (ILMS) for the following
tumor markers: CA19 Carbohydrate Antigen 19-9 (CA 19-9), Calcitonin, Prostate Specific Antigen (PSA), from 2017 to 2020. Data from January 1st, 2017 till
December 31st, 2019 was recorded and compared with the test volume data from January 1st, 2020 till December 31st, 2020. Number of tests performed in the prior
3 years were compared with tests performed in 2020, specifically looking at changes during the lockdown period in 2020 (1st March – 9 th April) and compared with
the same period in preceding years.
Results: During the four-year period, a total of 6,530 tests were performed for CA19-9, 893 for Calcitonin, and 54,769 for PSA. Year 2019 recorded the highest volume
for all 3 tests with test volumes increasing continuously from 2017 to 2019. Number of tests performed decreased throughout the year 2020 for Calcitonin and PSA,
whereas volume of tests for CA19-9 only reduced during the lockdown period while increased in the non-lockdown period as compared to previous years. Highest
percent decline during the 2020 lockdown period was seen for Calcitonin (-62.5%), followed by PSA (-51.8%) and CA19-9 (-19%).
Conclusion: In conclusion, the amount of CA19-9, Calcitonin, and PSA tests performed in Karachi, Pakistan has drastically reduced due to the lockdown that was
mandated due to the COVID-19 outbreak. It is crucial that despite an imposed lockdown, regular cancer screening must continue.

1. Introduction
COVID-19 pandemic has caused unprecedented morbidity and
mortality globally [1]. Though the direct effects of COVID-19 are well
studied and documented, the indirect losses incurred financially, and
non-COVID related health issues are remain under-reported [2]. The
lockdowns imposed by the governments to curb the spread of the disease
resulted in significant financial losses in terms of businesses, jobs and
travel restrictions. Although some of these losses were predicted be
forehand and prepared for, healthcare sector, apart from COVID-19, is
one area that may have been overlooked.
Literature suggests multi-faceted consequences of COVID-19,
including exacerbation of pre-existing diseases [3]. One of the disease
groups where the effects of pandemic could be particularly detrimental
is cancer, specifically cancer screening. With over 19 million new cancer

cases in 2020 and almost 10 million cancer deaths; this group cannot be
overlooked irrespective of the pandemic situation [4]. COVID-19
pandemic could be harmful for such patients if it results in delayed di
agnoses and/or treatment. Travel restrictions, lockdowns imposed by
governments and general fear of visiting hospitals during acute rise in
COVID-19 cases may interfere with diagnosis and treatment of cancer
patients. Specially for cancer screening, delayed diagnosis can lead to
advanced tumor stages at first diagnosis, which leads to poorer treat
ment outcomes and increased morbidity and mortality in such patients
[5]. Pakistan being a low-middle-oncome country (LMIC), where med
ical resources are inadequate and healthcare facilities are scarce, maybe
at an additional danger of delayed diagnosis of cancer patients.
The purpose of this study is to assess how the COVID-19 pandemic
affected cancer screening at a large tertiary care setting in the city of
Karachi, the third largest city in the world, and to identify if there has
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been any decrease in cancer screening during the ongoing pandemic.

4. Discussion

2. Methods

The results of our study show a decrease in cancer screening tests
during the pandemic, especially during the lockdown period. This could
result in delayed diagnosis and treatment of cancer patients which can
be detrimental for patients already facing a global catastrophe.
The results are in-line with findings from other regions as well. Patt
et al. performed a study in US population and reported that at the peak
of pandemic in April 2020, screenings for breast, colon, prostate, and
lung cancers were lower by 85%, 75%, 74%, and 56%, respectively [6].
They reported that institutional providers had greater reductions in
delivery of cancer care. Similar results were reported by Ferrari et al.
from Italy who reported a 62% decrease in PSA tests requests during the
lockdown period [7].
Although the results in our study are in-line with the results from
other regions; the consequences could be more severe for Pakistan due
an already low cancer screening as compared to developed countries.
The CA19-9 tests volumes, apart from the lockdown period, saw a
rebound increase in 2020 as compared to previous years. This increase
can be attributed to tests that were not performed during the lockdown
period. Also, the tests performed each year has been continuously
increasing from 2017 onwards. Surprisingly, no such rebound increase
was seen for Calcitonin and PSA, which could be alarming, if the cancer
screening was never performed on such patients.
The overall decrease in cancer screening tests performed could be
attributed to a number of reasons. One reason that could be the fear of
leaving the house during the lockdown period. A study conducted March
2020 in Karachi, Pakistan showed that 62.5% of respondents claimed to
have feelings of anxiety due to the pandemic [8]. Another reason could
be logistic difficulties due to closure of public transportation during
lockdown. This made it harder for patients relying on public trans
portation to access healthcare facilities [9]. Another reason may be
possible confusion on whether testing services were still available. The
pandemic caused many businesses and clinics to suspend operations.
This may have led to assumption that cancer screening services were not
available during the lockdown period [10]. The poverty level of Pakistan
is projected to rise about 33.7% due to the pandemic [11]. This could
also be a reason for decreased testing during the pandemic period.
The limitation of our study is a single center design. Also, only 3
cancer screening tests were studied. But this was a first of its kind study
from Pakistan which can give insight about impact of COVID-19 on
healthcare delivery in the region. The results of the study can be used to
educate patients and healthcare providers about the potential gaps
created in healthcare delivery and address them using structured
educational approaches so essential health work in not missed.

A retrospective observational study was conducted at the clinical
chemistry laboratory at the Department of Pathology & Laboratory
Medicine, Aga Khan University Hospital (AKUH), Karachi Pakistan,
which serves as a national reference lab for the country. With a large
network of more than 290 phlebotomy centers and outreach laboratories
spread across the country, it accommodates test requests from all the
provinces. The laboratory operates to highest standards of quality and
was the first lab to be accredited by College of American Pathologists
(CAP) as well as Joint Commission International Accreditation (JCIA).
Data for test volumes was extracted from the Integrated Laboratory
Management System (ILMS) for the following tumor markers: CA19
Carbohydrate Antigen 19–9 (CA 19–9), Calcitonin, Prostate Specific
Antigen (PSA), from 2017 to 2020.
Data from January 1st, 2017 till December 31st, 2019 was recorded
and compared with the test volume data from January 1st, 2020 till
December 31st, 2020. No patient-related information was gathered
hence ethical approval was not required.
Frequencies and means were calculated for the volume of tests per
formed during the 4-year period. Number of tests performed in the prior
3 years were compared with tests performed in 2020, specifically
looking at changes during the lockdown period in 2020 (1st March – 9th
April) and compared with the same period in preceding years. The
changes in the number of tests performed were expressed in terms of
percent change. Microsoft Excel 2019 was used for data analysis.
3. Results
During the four-year period, a total of 6530 tests were performed for
CA19-9, 893 for Calcitonin, and 54,769 for PSA. Year 2019 recorded the
highest volume for all 3 tests with test volumes increasing continuously
from 2017 to 2019. Number of tests performed decreased throughout
the year 2020 for Calcitonin and PSA, whereas volume of tests for CA199 only reduced during the lockdown period while increased in the nonlockdown period as compared to previous years. Highest percent decline
during the 2020 lockdown period was seen for Calcitonin (− 62.5%),
followed by PSA (− 51.8%) and CA19-9 (− 19%). The means of tests
along during the lock down period and the non-lockdown period, along
with the percent change are given in Table 1.

Table 1
Comparison of tests performed in 2020 with mean tests performed 2017–2019.

5. Conclusion

Tests performed in
2020

Mean tests performed
(2017–2019)

Percent
change

Total period
Lockdown
perioda
No lockdown
period
CALCITONIN

1798
145

1577.33
179

12.3%
¡19%

1653

1398.33

15.4%

Total period
Lockdown
perioda
No lockdown
period
PSA

211
12

227.33
32

¡7.2%
¡62.5%

199

195.33

1.8%

The following information is required for submission. Please note
that failure to respond to these questions/statements will mean your
submission will be returned. If you have nothing to declare in any of
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Total period
Lockdown
perioda
No lockdown
period

12778
759

13997
1576

¡8.7%
¡51.8%

Please state any conflicts of interest

12019

12421

¡3.2%

In conclusion, the amount of CA19-9, Calcitonin, and PSA tests
performed in Karachi, Pakistan has drastically reduced due to the
lockdown that was mandated due to the COVID-19 outbreak. It is crucial
that despite an imposed lockdown, regular cancer screening must
continue.

CA19-9

a

Annals of medicine and surgery

None.

Lockdown period was between March 1 and April 9, 2020.
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